CONTROL BIONICS LIMITED — Investor Presentation 2024

Jul 30, 2024

==> picture [255 x 84] intentionally omitted <==

Next-generation assistive technology and data measurement

T E C H K N O W P R E S E N T A T I O N J E R E M Y S T E E L E , C E O 3 1 J U L Y 2 0 2 4

==> picture [556 x 518] intentionally omitted <==

==> picture [49 x 43] intentionally omitted <==

==> picture [49 x 43] intentionally omitted <==

C O N T R O L B I O N I C S . C O M | A S X : C B L

==> picture [1440 x 80] intentionally omitted <==

Disclaimer

This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter covered in it. The information in this presentation, whether written or verbal, has been prepared without taking into account the commercial, financial or other needs of any individual or organisation.

Certain information may relate to protected intellectual property rights owned by Control Bionics Limited (Control Bionics) and its subsidiaries (together the Group).

While due care has been taken in compiling the information based on the information available to Control Bionics at the date of the presentation material, neither Control Bionics nor its officers or advisors or any other person warrants the accuracy, reliability, completeness or timeliness of the information or guarantees the commercial or investment performance of the Group.

The information does not constitute advice of any kind and should not be relied upon as such. Investors must make their own independent assessment of the Group and undertake such additional enquiries as they deem necessary or appropriate for the own investment purposes. Any and all use of the information is at your own risk.

No representations, warranty or assurance (express or implied) is given or made in relation to any forward looking statement by and person (including Control Bionics). In particular, no representation ,warranty or assurance (express or implied) is given in relation to any underlying assumptions or that any forward looking statement will be achieved. Actual future events may vary materially from the forward looking statements and the assumptions on which the forward looking statements are based.

Subject to any continuing obligations under applicable law or any relevant listing rules of the Australian Securities Exchange, Control Bionics disclaims any obligation or undertaking to disseminate any updates or revisions to any forward looking statements in these materials to reflect any change in expectations to any forward looking statements or any change in events, conditions or circumstances on which and such statement is based. Nothing in these materials shall under any circumstances create an implication that there has be been no change in the affairs of the Group since the date of these materials.

==> picture [1440 x 80] intentionally omitted <==

I N T R O D U C T I O N

On the cusp of rapid global growth

A proven medical device company with sizeable global sales of core products that we design and manufacture

==> picture [69 x 69] intentionally omitted <==

==> picture [69 x 67] intentionally omitted <==

==> picture [79 x 78] intentionally omitted <==

Long history of Core business Regulatory expertise with our clearance and continues to grow world-first, best-inpatent protected organically in class proprietary in US, AU, UK, Australia, the US technology Japan and Europe and Japan

Blue sky and Many levers for Near cash flow diversification growth with new breakeven* opportunities with products, uses, excluding sales next generation markets, and from new solutions channel partners initiatives

• before corporate overheads

==> picture [1440 x 80] intentionally omitted <==

I N T R O D U C T I O N EMG technology: the heart of our solutions

==> picture [786 x 443] intentionally omitted <==

==> picture [1440 x 80] intentionally omitted <==

I N T R O D U C T I O N

EMG technology: how it works

==> picture [127 x 145] intentionally omitted <==

==> picture [125 x 34] intentionally omitted <==

==> picture [93 x 111] intentionally omitted <==

==> picture [125 x 34] intentionally omitted <==

==> picture [111 x 29] intentionally omitted <==

----- Start of picture text -----

An EMG signal is
detected.
----- End of picture text -----

==> picture [157 x 81] intentionally omitted <==

==> picture [61 x 61] intentionally omitted <==

==> picture [125 x 33] intentionally omitted <==

==> picture [128 x 49] intentionally omitted <==

----- Start of picture text -----

Our patented code
creates a “switch”
to operate devices
----- End of picture text -----

==> picture [117 x 69] intentionally omitted <==

==> picture [66 x 109] intentionally omitted <==

==> picture [110 x 96] intentionally omitted <==

==> picture [86 x 91] intentionally omitted <==

Your brain sends a thought like “move my index finger”.

To move your finger, an electrical signal is created and Electromyography (EMG) is the detection of this signal.

Our core IP uses smart algorithms to detect, analyse and convert your body’s bioelectrical EMG into code so a user can select an item and operate a device.

Users can type, generate speech, send emails, browse the web, stream entertainment, access social apps, control their environment (lights, electric beds), play with toys, and more.

==> picture [82 x 82] intentionally omitted <==

EMG CAPTURES, RECORDS AND INTERPRETS ELECTRICAL ACTIVITY PRODUCED IN YOUR BODY’S MUSCLES WHEN YOU MOVE

==> picture [112 x 37] intentionally omitted <==

Markets

Assistive Mobility

==> picture [218 x 189] intentionally omitted <==

==> picture [218 x 189] intentionally omitted <==

Assistive Communication Data Measurement

A S S I S T I V E C O M M U N I C A T I O N

==> picture [112 x 37] intentionally omitted <==

==> picture [118 x 102] intentionally omitted <==

==> picture [279 x 64] intentionally omitted <==

Our fastest near term path to growth

What Is It

Works like a switch that turns into a mouse click, letting the user control their communication and software

Minimum $1.3bn globally

Market Size

Current sales Speech Language Pathologists (SLPs), industry bodies, clinics, schools, and hospitals model (retail) give demos and recommend our products

==> picture [38 x 34] intentionally omitted <==

==> picture [38 x 36] intentionally omitted <==

==> picture [33 x 34] intentionally omitted <==

New growth sales model (wholesale)

NEW PARTNERS

CURRENT SALES

NEW MARKETS

Currently building distributor partnerships where our strong patent portfolio and lack of competition give us the best market opportunity

Japan was our first market for the new NeuroNode® wholesale strategy in 2023, with initial sales recorded in 1H24

Our next focus is the UK and select continental European countries for disabilities, including a significant cerebral palsy market of some 400,000 people

==> picture [157 x 81] intentionally omitted <==

Potential Catalyst: In August we find out if we secure a new US Insurance Code

Impact: Materially lift our US prices and pursue a new revenue-sharing sales strategy with partners/resellers

A S S I S T I V E M O B I L I T Y

==> picture [112 x 37] intentionally omitted <==

==> picture [342 x 458] intentionally omitted <==

==> picture [118 x 103] intentionally omitted <==

==> picture [274 x 74] intentionally omitted <==

==> picture [231 x 69] intentionally omitted <==

The world’s first autonomous wheelchair

What Is It

A patent-pending module, developed with Deakin University, retrofits powered wheelchairs for safer, independent home travel controlled by the user's intentions Minimum $100m globally

Market Size

Current sales With TGA approval granted in June, we expect to begin sales to Australian users soon. model (retail) FDA submission is anticipated in Q4 FY25

==> picture [34 x 34] intentionally omitted <==

==> picture [38 x 34] intentionally omitted <==

New growth CURRENT SALES sales model (wholesale)

NEW MARKETS

NEW PARTNERS

First sales expected in coming months in Australia

The recent $A575k ALS grant will Currently building distributor help us research the best entry partnerships with powered paths into the US wheelchair manufacturers

New powered 2 million wheelchairs sold globally each year

B E Y O N D A S S I S T I V E T E C H N O L O G Y

==> picture [112 x 37] intentionally omitted <==

==> picture [109 x 94] intentionally omitted <==

The new NeuroStrip is a game-changer

==> picture [870 x 490] intentionally omitted <==

B E Y O N D A S S I S T I V E T E C H N O L O G Y

==> picture [112 x 37] intentionally omitted <==

==> picture [109 x 94] intentionally omitted <==

NEUROSTRIP

==> picture [114 x 53] intentionally omitted <==

Blue sky potential with endless uses

What Is It

A world-first all-in-one accelerometer and EMG device that measures physiological data like unintentional muscle movement

Market strategy: Enter those with the fastest, lowestcost access with no extra approvals.

Market Size

Blue sky

==> picture [36 x 36] intentionally omitted <==

Sports science

Current sales It’s a new product that will not sell retail model (retail)

==> picture [34 x 34] intentionally omitted <==

New growth CURRENT SALES sales model (wholesale) The first batch of commercial-grade NeuroStrips was recently manufactured

NEW MARKETS

Our initial focus is to leverage our market position in our existing markets of Australia, US and Japan for sales

==> picture [37 x 53] intentionally omitted <==

Rehab and biofeedback

==> picture [42 x 47] intentionally omitted <==

Movement disorders Dysphagia

==> picture [37 x 34] intentionally omitted <==

NEW PARTNERS

We have commenced discussions in the US, Incontinence Australia and Japan for potential partnerships for NeuroStrip distribution

F I N A N C I A L S

==> picture [112 x 37] intentionally omitted <==

==> picture [599 x 329] intentionally omitted <==

----- Start of picture text -----

R E V E N U E ( A $ m )
E B I T D A ( $ A m )
25%
----- End of picture text -----

==> picture [653 x 310] intentionally omitted <==

----- Start of picture text -----

E M P L O Y E E S % S A L E S
----- End of picture text -----

==> picture [117 x 102] intentionally omitted <==

Gaining traction year on year

• 300 systems sold in our key markets in FY23.

• FY23 revenue up an impressive 25% over FY22.

• US is the strongest market as the strength of our team and time in-market delivers.

• Strong cost control saw losses narrow.

• Australian operations deliver positive EBITDA for FY23. US operations are expected to be monthly breakeven by Dec-24.

• Board revitalisation with new board member, Professor Rob Heard and CEO appointment of Jeremy Steele.

==> picture [1440 x 80] intentionally omitted <==

P E O P L E

Experienced leadership

Jeremy Steele

B O A R D

==> picture [174 x 117] intentionally omitted <==

==> picture [117 x 116] intentionally omitted <==

==> picture [163 x 109] intentionally omitted <==

Shannon Boothroyd

Proven senior finance and accounting professional with more than 20 years of extensive experience in accounting, auditing and financial analysis with both Chartered Accountant (CAANZ) and Certified Public Accountant (AICPA-USA) designations.

Roger Hawke

Chairman Independent Non Executive Director

Jeremy Steele Managing Director CEO

Peter Ford

Founder & Non Executive Director

==> picture [115 x 114] intentionally omitted <==

==> picture [175 x 116] intentionally omitted <==

==> picture [174 x 116] intentionally omitted <==

Todd Tyler

Prof Rob Heard

Independent Non Executive Director

Damian Lismore

Independent Non Executive Director

Brett Crowley Company Secretary

James Schorey

G e t i n t o u c h

C O M P A N Y

I N V E S T O R R E L A T I O N S

==> picture [134 x 129] intentionally omitted <==

==> picture [135 x 129] intentionally omitted <==

J O E D U R A K

J E R E M Y S T E E L E C E O C O N T R O L B I O N I C S

E X E C U T I V E D I R E C T O R & F O U N D E R L Y N X A D V I S O R S

j s t e e l e @ c o n t r o l b i o n i c s . c o m + 6 1 4 3 3 2 2 9 4 7 0

j o e @ l y n x a d v i s o r s . c o m . a u + 6 1 4 1 4 4 6 5 5 8 2

C O N T R O L B I O N I C S . C O M | A S X : C B L

==> picture [371 x 635] intentionally omitted <==